[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360101-105":59,"doc-detail-360101-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","siddha-formulations-for-cancer-management-a-review-of-preclinical-and-clinical-data","Siddha formulations for cancer management - A review of preclinical and clinical data","","Cancer remains a major public health challenge in India, with 1,461,427 new cases reported in 2022. This review evaluates multiple Siddha formulations for anticancer activity and summarizes promising in vitro findings, especially against cervical, breast, and liver cancers. Cytotoxicity was assessed using MTT assays, with IC₅₀ values spanning 0.075–1000 µg/mL, indicating wide potency variation. Safety studies covering acute and chronic toxicity are available for many formulations, while advanced molecular analyses such as Annexin V and gene expression remain limited.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/siddha-formulations-for-cancer-management-a-review-of-preclinical-and-clinical-data/360101/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/siddha-formulations-for-cancer-management-a-review-of-preclinical-and-clinical-data/360101.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the review focus on regarding Siddha formulations?","Question",{"text":113,"@type":114},"It reviews various Siddha formulations evaluated for anticancer activity and summarizes evidence from preclinical and clinical data.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was cytotoxicity measured in the evaluated studies?",{"text":118,"@type":114},"Cytotoxicity was assessed using MTT assays, reporting IC₅₀ values that range from 0.075 µg/mL to 1000 µg/mL.",{"name":120,"@type":111,"acceptedAnswer":121},"What limitations in advanced molecular testing were noted?",{"text":122,"@type":114},"Advanced molecular analyses such as Annexin V and gene expression studies were limited across many of the formulations.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360101,1790269554,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","[www.bioinformation.net](www.bioinformation.net)  \nVolume 22(3)  \nReview  \nReceived March 1, 2026; Revised March 31, 2026; Accepted March 31, 2026, Published March 31, 2026  \nDOI: 10.6026/973206300221582  \nSJIF 2026 (Scientific Journal Impact Factor for 2026) = 8.478 2022 Impact Factor (2023 Clarivate Inc. release) is 1.9  \nDeclaration on Publication Ethics:  \nThe author’s state that they adhere with COPE guidelines on publishing ethics as described elsewhere at [https://publicationethics.org/. The](https://publicationethics.org/. The) authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.  \nDeclaration on official E-mail:  \nThe corresponding author declares that lifetime official e-mail from their institution is not available for all authors  \nLicense statement:  \nThis is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License  \nComments from readers:  \nArticles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.  \nDisclaimer:  \nBioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain after adequate peer/editorial reviews and editing entertaining revisions where required. The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required.  \nEdited by P Kangueane  \nCitation: Balasubramani et al. Bioinformation 22(3): 1582-1592 (2026)  \nSiddha formulations for cancer management: Areview of preclinical and clinical data  \nAbarna Balasubramani1,*, I. Shaira Banu1, Jinavani Jeevagan1, Suresh Ramasamy2, Sathish Adithya Rajathinakaran1,* & Medini Elanchezhian3  \n1Department of Nanju Maruthuvam (Siddha Toxicology), National Institute of Siddha, (Affiliated with the Tamil Nadu Dr. M.G. R Medical University), Ministry of Ayush, Chennai, Tambaram Sanatorium, Tamil Nadu, India; 2Department of Gunapadam (Siddha Pharmacology), National Institute of Siddha,(Affiliated with the Tamil Nadu Dr. M.G. R Medical University), Ministry of Ayush, Chennai, Tambaram Sanatorium, Tamil Nadu, India; 3Department of Siddhar Yoga Maruthuvam, Government Siddha Medical College, (Affiliated with the Tamil Nadu Dr. M.G. R Medical University), Ministry of Ayush, Chennai, Tamil Nadu, India;  \n*Corresponding author  \nAffiliation URL:  \n[https://nischennai.org/main/nanju-maruthuvam/](https://nischennai.org/main/nanju-maruthuvam/)  \n[https://gsmcchennai.ac.in](https://gsmcchennai.ac.in)  \nAuthor contacts:  \nAbarna Balasubramani-E-mail: [abu.abarna96@gmail.com](abu.abarna96@gmail.com)  \nI Shaira Banu-E-mail: [shairabanuismail12@gmail.com](shairabanuismail12@gmail.com)  \nJinavani [Jeevagan-E-mail: jinajeeva24@gmail.com](Jeevagan-E-mail: jinajeeva24@gmail.com)  \nSuresh Ramasamy-E-mail: [suresh03051994@gmail.com](suresh03051994@gmail.com)  \nSathish Adithya Rajathinakaran-E-mail: [adithyasa83@gmail.com](adithyasa83@gmail.com)  \n[Medini Elanchezhian-E-mail: drmedini22@gmail.com](Medini Elanchezhian-E-mail: drmedini22@gmail.com)  \nAbstract:  \nCancer continues to be a significant public health challenge in India, with 1,461,427 new cases reported in 2022. A review of various Siddha formulations evaluated","cbCait4pnQrmTJYX","https://ap.wps.com/l/cbCait4pnQrmTJYX","pdf",702468,11,"English","# Abstract\n# Background\n# Review Scope and Methods\n## Preclinical evidence\n## Clinical evidence\n# Safety and Mechanistic Findings\n# Conclusions and Recommendations","[{\"question\":\"What does the review focus on regarding Siddha formulations?\",\"answer\":\"It reviews various Siddha formulations evaluated for anticancer activity and summarizes evidence from preclinical and clinical data.\"},{\"question\":\"How was cytotoxicity measured in the evaluated studies?\",\"answer\":\"Cytotoxicity was assessed using MTT assays, reporting IC₅₀ values that range from 0.075 µg/mL to 1000 µg/mL.\"},{\"question\":\"What limitations in advanced molecular testing were noted?\",\"answer\":\"Advanced molecular analyses such as Annexin V and gene expression studies were limited across many of the formulations.\"}]","Siddha formulations for cancer management - A review of preclinical and clinical data | PDF",1790138756,28]